EGFR and non-small cell lung carcinoma: For that purpose, we first studied the proteome of EVs from a pair of NSCLC cell lines with activating mutations in the EGFR gene, alongside the EGFR T790M resistance mutation, and with different degrees of osimertinib refractoriness.